---
title: "Ipsen SA FY 2025 core operating income rises 16.7% to EUR 1.29 billion"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275705399.md"
datetime: "2026-02-12T06:00:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275705399.md)
  - [en](https://longbridge.com/en/news/275705399.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275705399.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275705399.md) | [English](https://longbridge.com/en/news/275705399.md)


# Ipsen SA FY 2025 core operating income rises 16.7% to EUR 1.29 billion

Ipsen SA reported its full year (FY) 2025 financial results, posting total sales of EUR 3,675.9 million, an increase of 8.1% compared to the previous year. Core operating income for FY 2025 stood at EUR 1,294.1 million, reflecting a significant rise of 16.7%. For 2026, Ipsen SA provided financial guidance, targeting total sales growth of more than 13.0% and a core operating margin above 35.0% of total sales. The company expects accelerated growth from its portfolio excluding Somatuline, as well as continued growth in Somatuline sales due to generic lanreotide production challenges. The guidance also anticipates increased R&D expenses from early and mid-stage external innovation opportunities. Ipsen SA highlighted expectations for five major regulatory and clinical milestones in 2026, alongside a full data readout for IPN10200 in an aesthetics indication. The company plans to release its first quarter 2026 sales on April 23, 2026. Comprehensive audited financial statements will be made available on its website in due course. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164329-en) on February 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [China Merchants CSI All Share Medical Apparatus and Instruments ETF (159898.CN)](https://longbridge.com/zh-HK/quote/159898.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)

## 相關資訊與研究

- [Euroapi SA Earnings Call: Discipline Amid Declining Sales](https://longbridge.com/zh-HK/news/278290773.md)
- [Kepler Capital  Sticks to Its Hold Rating for Ipsen (0MH6)](https://longbridge.com/zh-HK/news/278642986.md)
- [BK Technologies Beats 2025 Guidance, Sets 2026 Targets](https://longbridge.com/zh-HK/news/278879791.md)
- [IOI Corporation Berhad Reports Production Results for the Month of February 2026](https://longbridge.com/zh-HK/news/279074071.md)
- [Sampo launches new long-term incentive scheme for 2026–2028](https://longbridge.com/zh-HK/news/278909032.md)